reports
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect...
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the , to take place on Monday, May 20, 2024, at the NAS...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 15,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 2,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 I...
Super League Announces First Quarter 2024 Financial Results
Super League Announces First Quarter 2024 Financial Results ~ Q1 2024 Revenues Increase 27% from Q1 2023 to $4.2 Million ~ ~ Strategic Partnerships Formed with Chartis and GSTV ~ SANTA MONICA, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), a leading creator and publisher of content experiences and media solutions across the world’s largest immersive platforms, has released its first quarter 2024 financial results in the form of a . A webinar hosted by Ann Hand, CEO of Super League, and Clayton Haynes, CFO of Super League, will be streamed beginning...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Pr...
Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sa...
Spero Therapeutics Announces First Quarter 2024 Operating Results and ...
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWI...
Longeveron Announces First Quarter 2024 Financial Results and Provides...
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update Phase 2b clinical trial evaluating Lomecel-BTM in rare pediatric disease HLHS on track for completing enrollment by end of 2024Data from Phase 2a clinical trial evaluating Lomecel-BTM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer’s Association International ConferenceCompleted two financings in April raising gross proceeds of $11.4 million to fund continued clinical developmentFocused expenditure management reduced first quarter Total Operating Expenses 8% year-...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
Cardiff Oncology to Present at Upcoming Investor Conferences in May SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in May 2024. Details of the presentations can be found below. H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQLocation: The Nasdaq Headquarters, New York CityPresenter: Mark Erlander, CEOFormat: Fireside ChatDate:...
Moody's Ratings assigns Ba3 rating to new senior notes issued by Icahn...
Moody's Ratings (Moody's) has assigned a Ba3 rating to $500 million of backed senior unsecured notes due 2030 issued by Icahn Enterprises L.P. (IEP). Moody's said that the new debt issuance extends the maturity on IEP's outstanding debt but is otherwise neutral to its credit profile because the ne...
Super League Partners with Skechers and Century Games Opens the Compan...
Super League Partners with Skechers and Century Games Opens the Company’s First Virtual Store in Livetopia’s Topia Mall on Roblox Immersive Experience Features an Interactive Treasure Hunt to Win Exclusive Skechers Digital Items SANTA MONICA, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:SLE), a leading creator and publisher of content experiences and media solutions across the world’s largest immersive platforms, has joined forces with , The Comfort Technology Company® (NYSE:SKX), to open the company’s first virtual store through an immersive experience in Roblox Livetopia’s Topia ...
Longeveron Announces Board of Directors Planned Transitions
Longeveron Announces Board of Directors Planned Transitions Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron BoardDr. Roger Hajjar, former head of R&D at Ring Therapeutics, has been nominated as a candidate for the Board, subject to election at the Company’s Annual Meeting of StockholdersNeha Motwani, former managing director and senior healthcare investment banker at William Blair, Truist, and Oppenheimer and Company, also has been nominated as a candidate for the Board, subject to election at the Compan...
- Wedbush Research
GEO GEO GROUP INC. (THE)
2454 MEDIATEK INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TSCO TRACTOR SUPPLY COMPANY
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
QCOM QUALCOMM INC
PZZA PAPA JOHN'S INTERNATIONAL INC.
PSTG PURE STORAGE INC. CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NHI NATIONAL HEALTH INVESTORS INC.
MU MICRON TECHNOLOGY INC.
LTC LTC PROPERTIES INC.
LOW LOWE'S COMPANIES INC.
JCOM J2 GLOBAL INC.
INTC INTEL CORPORATION
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
35G GENPACT LIMITED
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
CHUY CHUY'S HOLDINGS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
ANAB ANAPTYSBIO INC.
OKTA OKTA INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
PRPL PURPLE INNOVATION
LEGH LEGACY HOUSING CORP
CRNC CERENCE
SMCI SUPER MICRO COMPUTER
U INC.
PLTR UNITY SOFTWARE
VOR PALANTIR TECHNOLOGIES
PLTK VOR BIOPHARMA
SNOW PLAYTIKA HOLDING
RBLX SNOWFLAKE INC. CLASS A
GHLD ROBLOX
MRVL GUILD HOLDINGS
STX MARVELL TECHNOLOGY INC
ALIT SEAGATE TECHNOLOGY HLDGS PLC
UWMC FOLEY TRASIMENE ACQUISITION CORP
ATXS UWM HLDGS CORP
CCSI ASTRIA THERAPEUTICS INC
GFS CONSENSUS CLOUD SOLUTIONS INC
TYRA GLOBALFOUNDRIES INC
SOUN TYRA BIOSCIENCES INC
GETY SOUNDHOUND AI INC
GTBIF GETTY IMAGES HOLDINGS INC
SKLZ GREEN THUMB INDUSTRIES INC.
DNTH SKILLZ INC
DIANTHUS THERAPEUTICS INC
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
Savara Reports First Quarter 2024 Financial Results and Provides Busin...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. “The IMPALA-2 trial remains on-track and we look forward to reporting top line results by the end of the second quarter,” said Matt Pauls, Chair and CEO, Savara. “Following that, and assuming positive data, we expect to file a BLA in the first half of 2025. Importantly, with $143 million in cash and investments, we believe we are capitalized into ...
Spero Therapeutics to Report First Quarter 2024 Financial Results and ...
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not inten...
- Laura Chico
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
Savara to Present at the Citizens JMP Life Sciences Conference
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Busin...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update - In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib’s antitumor activity both as a single agent and in combination, highlighting its broad activity across all mCRC - - In SCLC and ovarian cancer, preclinical data presented at AACR highlighted onvansertib’s acti...
Longeveron to Report First Quarter 2024 Financial Results and Host Con...
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET. Conference Call Details: Conference Call Number: 1.877.407.0789 Conference ID: 13745868 Call meTM...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.